產(chǎn)品名稱：BI-847325

BI-847325生物活性：

? ? BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

BI-847325制備儲(chǔ)備液：

濃度溶解體積質(zhì)量	1mg	5mg	10mg
1mM	2.1032mL	10.5159mL	21.0318mL
5mM	0.4206mL	2.1032mL	4.2064mL
10mM	0.2103mL	1.0516mL	2.1032mL
50mM	0.0421mL	0.2103mL	0.4206mL

BI-847325臨床數(shù)據(jù)( 數(shù)據(jù)源于：http:// clinicaltrials.gov）

Conversion of different model animals based on BSA（Value based on data from FDA Draft Guidelines）


? ?Animal A (mg/kg)=Animal B（mg/kg）multiplied by?? ?AnimalBm系數(shù)/AnimalAm系數(shù)
? ?For example, to modify the dose of resveratrol uesd for a mouse(22.4mg/kg) to a dose based on the BSA for a rat, multiply 22.4mg/kg by the Km factor for a mouse and zhen divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2mg/kg


? ?南京賽泓瑞生物科技有限公司是專業(yè)從事生化試劑、分子生物學(xué)試劑、實(shí)驗(yàn)耗材及實(shí)驗(yàn)儀器研發(fā)、銷售、服務(wù)為一體的專業(yè)性生物科技公司。本著服務(wù)科學(xué)的理念，賽泓瑞建立了生命科學(xué)研究工具的研發(fā)、生產(chǎn)、銷售及技術(shù)服務(wù)平臺(tái)，現(xiàn)已有數(shù)萬余種產(chǎn)品，并每年不斷開發(fā)新產(chǎn)品，為廣大的生命科學(xué)研究人員、醫(yī)學(xué)、藥學(xué)、農(nóng)業(yè)、環(huán)保等的科研人員提供科研工具性產(chǎn)品及技術(shù)服務(wù).
經(jīng)營(yíng)范圍：抑制劑、ELISA試劑盒、原代細(xì)胞和細(xì)胞株、化學(xué)試劑、蛋白、抗體、分子試劑和試劑盒。